Verana Health and Guardant Health partnered to combine regulatory-grade electronic health record datasets with clinicogenomic testing data, enabling biopharma researchers to connect tumor genomics and therapy decisions to real-world outcomes. The collaboration expands Verana’s coverage across solid tumors including lung, breast, and colorectal cancers. The companies said the integrated resources will help researchers validate biomarker-treatment correlations and support studies across longitudinal care pathways, including therapy response monitoring and recurrence tracking. By linking detailed molecular profiling with clinical trajectories, the partnership aims to reduce fragmentation in how sponsors interpret evidence from observational data. For drug developers, the immediate use case is accelerating biomarker-driven trial design and improving the evidentiary bridge between earlier translational findings and population-level clinical outcomes.